Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design
Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson, Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson
Abstract
BRAFV600 oncogenic driver mutations occur in 1-2% of non-small-cell lung cancers (NSCLCs) and have been shown to be a clinically relevant target. Preclinical/clinical evidence support the efficacy and safety of BRAF and MEK inhibitor combinations in patients with NSCLC with these mutations. We describe the design of PHAROS, an ongoing, open-label, single-arm, phase II trial evaluating the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with metastatic BRAFV600-mutant NSCLC, as first- or second-line treatment. The primary end point is objective response rate, based on independent radiologic review (per RECIST v1.1); secondary objectives evaluated additional efficacy end points and safety. Results from PHAROS will describe the antitumor activity/safety of encorafenib plus binimetinib in patients with metastatic BRAFV600-mutant NSCLC.
Trial registration: ClinicalTrials.gov NCT03915951.
Keywords: BRAFV600 mutation; binimetinib; clinical trial; efficacy; encorafenib; non-small-cell lung cancer; objective response rate; safety.
Source: PubMed